Conundrums in Treating HER2-Positive Early Breast Cancer

Dr. Sara A. Hurvitz, MD, FACP, discussed the challenges of selecting among the abundant therapies for HER2-positive early breast cancer. She provided insight on treatment approaches for small node-negative disease and high-risk patients, highlighting the importance of neoadjuvant therapy, systemic therapy selection, and response-guided approaches. Dr. Hurvitz emphasized the need for personalized therapy and the ongoing efforts to improve treatment outcomes for patients.